Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Age Limit Override Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentQualChoicePolicy HIM.PA.177

    Clinical Policy: Age Limit Override

    Customize your policy alerts

    Sign up for QualChoice Policy HIM.PA.177 alerts

    Get alerted when Policy HIM.PA.177 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs medical necessity review and approval criteria when a member's age exceeds a health plan-approved formulary age limit for a drug that does not otherwise require prior authorization. Affects providers submitting requests for age limit overrides under the QualChoice (Centene-affiliated) health plans.

    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Age Limit Override
    Policy CodePolicy HIM.PA.177
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionProvider must submit clinical documentation (office chart notes, lab results, or other clinical information) showing the member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    Age limit exceededTrigger condition
    Examples listedExample agents
    Not aspirinAspirin handling

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Age Limit Overrides

    Initial Therapy

    Covered when ALL of the following are met for initial approval:

    Initial Approval - Age Limit Override: 1. Request is for a formulary drug.

    All requests for non-formulary drugs should be reviewed against HIM.PA.103 Brand Name Override and Non-Formulary Medications.

    Initial Approval - Exclude aspirin: 2. Request is for a drug other than aspirin.

    Aspirin is approvable only for members 45 to 79 years of age.

    Initial Approval - Age exceed: 3. Member's age exceeds the health plan-approved age limit.

    Supported indication

    • 4a: Prescribed indication is FDA-approved.
    • 4b.i: NCCN Drug Information and Biologics Compendium level of evidence 1, 2A, or 2B.

      See Appendix D.

    • 4b.ii: Evidence from at least two high-quality, published studies or evidence-based clinical practice guidelines that: (1) adequately represent the member's clinical characteristics, age, and diagnosis; (2) adequately represent the prescribed drug regimen; (3) demonstrate clinically meaningful outcomes from the drug therapy; and (4) use appropriate experimental design and methods.

      See Appendix F for additional information.

    • 4b.iii: Micromedex DrugDex with strength of recommendation Class I or IIa.

      See Appendix D.

    • 4b.iv: For states with state-specific pediatric supportive evidence regulations, refer to Appendix G.

      State addendums may apply.

    Initial Approval - Not excluded use: 5. Request is not for a benefit-excluded use (e.g., cosmetic).
    Initial Approval - Quantity limit: 6. Requested dose does not exceed health plan-approved quantity limit.

    Requests exceeding the health plan-approved quantity limit should also be reviewed against CP.PMN.59 Quantity Limit Override and Dose Optimization.

    Initial Approval - FDA max dose: 7. Dose does not exceed the FDA-approved maximum recommended dose for the relevant indication.

    Continuation Therapy

    Covered when ALL of the following are met for continued therapy:

    Continued Therapy - Eligibility: 1. Member meets one of the following: a) currently receiving medication via Centene benefit or has previously met initial approval criteria; OR b) currently receiving medication and enrolled in a state/product with continuity of care regulations.

    Refer to state-specific addendums CC.PHARM.03A and CC.PHARM.03B.

    Continued Therapy - Response: 2. Member is responding positively to therapy.
    Continued Therapy - Quantity limit: 3. Requested dose does not exceed health plan-approved quantity limit.
    Continued Therapy - Dose increase: 4. If request is for a dose increase, new dose does not exceed the FDA-approved maximum recommended dose for the relevant indication.

    Requests for benefit-excluded uses, including cosmetic indications, are not authorized under this policy. Such requests should be denied or redirected per plan rules and applicable exclusions. Benefit-excluded uses (e.g., cosmetic) are explicitly listed as non-authorizable reasons in the Initial Approval criteria.

    Use is not medically necessary when the requirements in the Initial or Continued Therapy sections are not met. Examples of noncompliance that render a request not medically necessary include: the drug is aspirin outside the approvable age window (aspirin is approvable only for members 45 to 79 years of age), the member’s age does not exceed the health plan-approved age limit, the requested indication lacks required supportive evidence for off-label use, the requested dose exceeds the health plan-approved quantity limit, or the dose exceeds the FDA-approved maximum recommended dose for the relevant indication. Requests failing any of these criteria should be considered not medically necessary.

    Initial Therapy — Age Limit Override

    Initial Therapy

    Covered when ALL of the following are met for initial approval (age limit override specific):

    Initial Therapy - See Initial Approval: Refer to the Initial Approval criteria set: request is for a formulary drug, not aspirin, member's age exceeds the plan age limit, prescribed indication is FDA-approved or supported by specified off-label evidence, request is not for a benefit-excluded use, requested dose does not exceed plan quantity limits, and dose does not exceed FDA maximum for the indication.

    Approval duration: 12 months.

    Continuation Therapy — Age Limit Override

    Continuation Therapy

    Covered when ALL of the following are met for continued therapy (age limit override specific):

    Continuation Eligibility: 1. Member currently receiving medication via Centene benefit or previously met initial approval criteria, OR is receiving medication and is enrolled in a state/product with continuity of care regulations.

    See CC.PHARM.03A and CC.PHARM.03B for state specifics. Approval duration: 12 months.

    Continuation Response: 2. Member is responding positively to therapy.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Age Limit Override: prior authorization requirement

    Age limit override applies when the request is for a formulary drug with a health plan-approved age limit that has been exceeded and the drug does not otherwise require prior authorization; the provider must submit clinical documentation and meet the policy criteria for approval.

    • Applies only to formulary drugs (non‑formulary requests follow HIM.PA.103).
    • Provider must submit supporting clinical documentation as described in policy.
    Step Therapy

    Quantity limit interactions

    If the requested dose exceeds the health plan‑approved quantity limit, the request must be reviewed in accordance with the Quantity Limit Override and Dose Optimization policy (CP.PMN.59).

    • Requested dose must not exceed the health plan‑approved quantity limit.
    • Requests exceeding quantity limits should be escalated to CP.PMN.59 for Quantity Limit Override and Dose Optimization review.
    Documentation Required

    Required clinical documentation

    Provider must submit documentation (such as office chart notes, laboratory results, or other clinical information) demonstrating that the member meets all approval criteria in this policy.

    • Include clinical notes and objective data showing indication, prior response, and that age criteria and evidence requirements are met.
    • Attach supporting studies or compendium references when the prescribed indication is off‑label and relies on cited evidence sources.
    Denial Risk

    Triggers for denial

    Requests may be denied when the approval criteria are not met, including specific triggers listed in the policy.

    • Member’s age does not exceed the health plan‑approved age limit.
    • Request is for aspirin outside the approvable age window (aspirin approvable only for members 45 to 79 years of age).
    • Request is for a benefit‑excluded use (e.g., cosmetic).
    • Requested dose exceeds the health plan‑approved quantity limit or exceeds the FDA‑approved maximum recommended dose for the relevant indication.
    • Prescribed off‑label indication lacks the required supportive evidence sources (NCCN/DrugDex/peer‑reviewed studies/state pediatric requirements).

    Quantity Limit Considerations

    QUANTITY LIMITS: varies by drug product
    Quantity limit requirementRequested dose must not exceed the health plan-approved quantity limit (requests exceeding the limit should be reviewed against CP.PMN.59 Quantity Limit Override and Dose Optimization).
    ApplicabilityApplies to formulary drugs; quantity limits vary by drug product and are set by the health plan.
    Related policyRequests exceeding the health plan-approved quantity limit should also be reviewed against CP.PMN.59 Quantity Limit Override and Dose Optimization.
    Approval impactIf requested dose exceeds the plan quantity limit, the use may be considered not medically necessary or denied unless overridden per CP.PMN.59.

    Definitions and Abbreviations

    DEFINITIONS: age limit (AL)
    AL (age limit) definitionAL = age limit (health plan-approved formulary age limit).
    Policy scopeApplies when member's age exceeds the health plan-approved age limit for a formulary drug that does not otherwise require prior authorization.
    Aspirin exceptionAspirin is approvable only for members 45 to 79 years of age and is excluded from general age limit overrides.
    DEFINITIONS: prior authorization (PA)
    PA (prior authorization) definitionPA = prior authorization; age limit override applies to formulary drugs with plan-approved age limits that do not otherwise require prior authorization, and requires submission of clinical documentation and meeting the policy criteria for approval.
    Provider actionProvider must submit documentation (office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria when requesting an age limit override.
    Review considerationsRequests are evaluated against initial or continued therapy criteria (formulary status, supported indication, not a benefit-excluded use, quantity and FDA dose limits); lack of required documentation may result in denial.

    Background

    This policy governs authorization when a member’s age is beyond a health plan–approved formulary age limit (AL). FDA-approved indications and labeled age ranges vary by product; approval for an age limit override requires that the prescribed indication be FDA-approved or, if off-label, supported by specified compendia or published evidence (for example, NCCN Drug Information levels 1/2A/2B, Micromedex DrugDex Class I/IIa, or at least two high-quality peer-reviewed studies meeting the policy’s criteria). The policy also excludes aspirin for most age overrides because aspirin is approvable only for members 45 to 79 years of age. Approval duration when criteria are met is 12 months.

    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Age Limit Override
    Policy CodePolicy HIM.PA.177
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionProvider must submit clinical documentation (office chart notes, lab results, or other clinical information) showing the member meets all approval criteria.
    SourceLink
    On This Page
    Coverage Criteria for Age Limit OverridesInitial Therapy — Age Limit OverrideContinuation Therapy — Age Limit OverrideProvider Actions and Documentation RequirementsQuantity Limit ConsiderationsDefinitions and AbbreviationsBackground